Dr. Magoola’s award-winning study, titled “Advancing Therapeutic and Vaccine Proteins: Switching from Recombinant to Ribosomal Delivery—A Humanitarian Cause,” was published in the International Journal of Molecular Sciences. The research emphasizes the advantages of mRNA technology over traditional methods, particularly in producing therapeutic proteins at a lower cost, making them more accessible to populations in developing countries.
In his acceptance remarks, Dr. Magoola expressed gratitude for the recognition and underscored the importance of affordable healthcare solutions. “The cost of therapeutic drugs and making protein vaccines is very expensive, hence not affordable to over 6.5 billion people all over the world,” he stated. He aims to inspire developing nations to manufacture their own therapeutic drugs, promoting self-sufficiency in healthcare.
Dr. Magoola’s achievements come on the heels of earning a Doctorate of Philosophy (PhD) from the European International University France earlier this year, further solidifying his status as a leading figure in biopharmaceutical research.